Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sabin inactivated poliovirus vaccine + bivalent oral poliovirus vaccine + bivalent oral poliovirus vaccine
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Oral
01
Overview
This is a sequential combination immunization regimen consisting of one dose of Sabin strain inactivated poliovirus vaccine (Sabin-IPV) followed by two doses of bivalent oral poliovirus vaccine (bOPV). The Sabin-IPV is an inactivated, injectable polio vaccine derived from attenuated (Sabin) strains of all three serotypes of poliovirus. It induces systemic immunity and helps prevent paralytic disease. The bOPV is a live, attenuated, oral polio vaccine containing only types 1 and 3 Sabin strains; it induces strong mucosal immunity in the gut to interrupt virus transmission. This sequential schedule aims to maximize both individual protection against paralysis and community protection by reducing viral shedding and transmission[1][2][3].
- Other names
- Sabin-IPV + bOPV + bOPV
02
Targets
Poliovirus type 1 capsid proteinWPV3 (Poliovirus type 3 capsid protein)
Beyond the preview
Go deeper on Sabin inactivated poliovirus vaccine + bivalent oral poliovirus vaccine + bivalent oral poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sabin inactivated poliovirus vaccine + bivalent oral poliovirus vaccine + bivalent oral poliovirus vaccine.